新型降糖药物在三种常见青少年的成年起病型糖尿病亚型上的应用

Application of new hypoglycemic drugs of the three most common types of maturity-onset diabetes of the young

青少年的成年起病型糖尿病(maturity-onset diabetes of the young, MODY)是一种异质性的单基因糖尿病,其中MODY1、MODY2和MODY3是常见的MODY亚型。近年来胰升糖素样肽1受体激动剂(GLP-1RA)、二肽基肽酶4抑制剂(DPP-4i)、钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)与葡萄糖激酶激动剂(GKA)等新型降糖药物在治疗糖尿病方面取得了良好的进展,本文结合目前最新的基础及临床证据,对上述三种MODY的发病机制、临床特征、关于新型降糖药物的诊疗进展作一综述,旨在为MODY的诊疗开拓更为安全有效的新方法。

Maturity-onset diabetes of the young(MODY)is a heterogeneous monogenic diabetes,in which MODY1,MODY2,and MODY3 are the most common subtypes.In recent years,new hypoglycemic drugs such as glucagon-like peptide-1 receptor agonists(GLP-1RA),dipeptidyl peptidase-4 inhibitors(DPP-4i),sodium-glucose co-transporter 2 inhibitors(SGLT2i),and glucokinase activators(GKA)have made good progress in the treatment of diabetes.Based on the latest basic and clinical evidence,the article reviews the pathogenesis,clinical features,diagnosis and treatment progress of new hypoglycemic drugs of the above three types of MODY,aiming to develop safer and more effective new ways for the diagnosis and treatment of MODY.